Esen İhsan, Bayramoğlu Elvan, Yıldız Melek, Aydın Murat, Karakılıç Özturhan Esin, Aycan Zehra, Bolu Semih, Önal Hasan, Kör Yılmaz, Ökdemir Deniz, Ünal Edip, Önder Aşan, Evliyaoğlu Olcay, Çayır Atilla, Taştan Mehmet, Yüksel Ayşegül, Kılınç Aylin, Büyükinan Muammer, Özcabı Bahar, Akın Onur, Binay Çiğdem, Kılınç Suna, Yıldırım Ruken, Aytaç Emel Hatun, Sağsak Elif
Fırat University Faculty of Medicine, Department of Pediatric Endocrinology, Elazığ, Turkey
Dr. Sami Ulus Maternity and Children’s Disease Training and Research Hospital, Clinic of Pediatric Endocrinology, Ankara, Turkey
J Clin Res Pediatr Endocrinol. 2019 May 28;11(2):164-172. doi: 10.4274/jcrpe.galenos.2018.2018.0210. Epub 2018 Nov 29.
To determine the demographic and biochemical features of childhood and juvenile thyrotoxicosis and treatment outcome.
We reviewed the records of children from 22 centers in Turkey who were diagnosed with thyrotoxicosis between 2007 to 2017.
A total of 503 children had been diagnosed with thyrotoxicosis at the centers during the study period. Of these, 375 (74.6%) had been diagnosed with Graves’ disease (GD), 75 (14.9%) with hashitoxicosis and 53 (10.5%) with other less common causes of thyrotoxicosis. The most common presenting features in children with GD or hashitoxicosis were tachycardia and/or palpitations, weight loss and excessive sweating. The cumulative remission rate was 17.6% in 370 patients with GD who had received anti-thyroid drugs (ATDs) for initial treatment. The median (range) treatment period was 22.8 (0.3-127) months. No variables predictive of achieving remission were identified. Twenty-seven received second-line treatment because of poor disease control and/or adverse events associated with ATDs. Total thyroidectomy was performed in 17 patients with no recurrence of thyrotoxicosis and all became hypothyroid. Ten patients received radioiodine and six became hypothyroid, one remained hyperthyroid and restarted ATDs and one patient achieved remission. Two patients were lost to follow up.
This study has demonstrated that using ATDs is the generally accepted first-line approach and there seems to be low remission rate with ATDs in pediatric GD patients in Turkey.
确定儿童及青少年甲状腺毒症的人口统计学和生化特征以及治疗结果。
我们回顾了土耳其22个中心在2007年至2017年期间被诊断为甲状腺毒症的儿童记录。
在研究期间,共有503名儿童在这些中心被诊断为甲状腺毒症。其中,375例(74.6%)被诊断为格雷夫斯病(GD),75例(14.9%)为桥本甲状腺毒症,53例(10.5%)为其他较罕见的甲状腺毒症病因。GD或桥本甲状腺毒症患儿最常见的临床表现为心动过速和/或心悸、体重减轻和多汗。370例接受抗甲状腺药物(ATD)初始治疗的GD患者的累积缓解率为17.6%。中位(范围)治疗期为22.8(0.3 - 127)个月。未发现预测缓解的变量。27例因疾病控制不佳和/或与ATD相关的不良事件接受二线治疗。17例患者接受了全甲状腺切除术,甲状腺毒症无复发,全部变为甲状腺功能减退。10例患者接受了放射性碘治疗,6例变为甲状腺功能减退,1例仍为甲状腺功能亢进并重新开始使用ATD,1例患者实现缓解。2例患者失访。
本研究表明,使用ATD是普遍接受的一线治疗方法,在土耳其,儿科GD患者使用ATD的缓解率似乎较低。